Roche terminates deal with Blueprint on Gavreto

24 February 2023
blueprint_medicines_large

Two and half years after the Swiss pharma giant paid $775 million up front to in-license the RET inhibitor, as part of a $1.7 billion deal with US biotech Blueprint Medicines (Nasdaq: BPMC), Roche (ROG: SIX) is pulling out of the deal to develop Gavreto (pralsetinib), citing “strategic reasons”.

Under the terms of the agreement, the termination will be effective 12 months from the notification date of February 22, 2023. During the transition period, Blueprint and Roche are mutually committed to ensuring a smooth transition process with no anticipated interruptions or changes to patient access. In addition, the company will explore options to advance and simplify the continued global commercialization and development of Gavreto.

"At Blueprint Medicines, we are dedicated to driving innovation and changing outcomes for patients with lung cancer. Gavreto is an important treatment option for patients with RET fusion-positive lung cancer and other RET-altered cancers, and we are committed to ensuring that patients being treated with Gavreto in the commercial and clinical trial settings continue to have access," said Kate Haviland, chief executive of Blueprint Medicines, whose shares closed down nearly 3% at $41.57 yesterday.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology